Zhao Xuan, Liu Yanfen, Qin Guohui, Ge Yan, Li Qinglong, Chen Xinfeng, Tian Ximei, Yu Yong, Ren Jiangtao, Zhang Yi
Biotherapy Center & Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.
Front Immunol. 2025 Jan 8;15:1504104. doi: 10.3389/fimmu.2024.1504104. eCollection 2024.
We reported the pseudoprogression in an elderly patient with advanced gastric cancer after chimeric antigen receptor (CAR)-T cell therapy. The hepatic metastases enlarged 1 month after CAR-T cell infusion and then shrunk the next month as seen through computed tomography scanning. Based on a comprehensive evaluation that includes imaging, pathology, serum tumor markers, and clinical symptoms, we arrived at a diagnosis of pseudoprogression after CAR-T cell therapy, which has not been reported in previous studies. In this report, we provide detailed descriptions of the patient's clinical presentation, imaging findings, treatment process, and follow-up outcomes. We believe that this case holds important implications for CAR-T cell therapy research and offers valuable insights for clinical practice.
我们报告了1例老年晚期胃癌患者在接受嵌合抗原受体(CAR)-T细胞治疗后出现假性进展的情况。通过计算机断层扫描可见,肝转移灶在CAR-T细胞输注后1个月增大,随后在下个月缩小。基于包括影像学、病理学、血清肿瘤标志物和临床症状在内的综合评估,我们诊断该患者为CAR-T细胞治疗后假性进展,此前研究中尚未有过此类报道。在本报告中,我们详细描述了患者的临床表现、影像学检查结果、治疗过程及随访结果。我们认为该病例对CAR-T细胞治疗研究具有重要意义,并为临床实践提供了有价值的见解。